Resources
17 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.
Posted 5/22/2020 (updated 3/28/2024)
Report details information and guidance for addressing substance use issues encountered during home visiting. Discusses substance use issues and the way home visiting can address those issues while supporting families. Features a number of questions and answers and includes discussion regarding home visiting in rural areas.
Posted 5/27/2020 (updated 3/28/2024)
Please see attached technical modules to help guide you as you work to address the opioid epidemic in your communities. They are a resource for you to identify best practices and implementation models for prevention, treatment, and recovery.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 3/26/2020 (updated 3/28/2024)
This webinar was held on March 23, 2020. The full webinar recording is included, please click.
Posted 10/12/2020 (updated 3/29/2024)
Built on an award winning, evidence-based prevention approach proven to reduce substance use, aggression and violence, our suite of digital products includes e-learning programs, an online educational game, and ancillary tools designed to provide schools, teachers, and parents with high quality content that can be used in school, at home, or in hybrid learning environments.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.